<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02105506</url>
  </required_header>
  <id_info>
    <org_study_id>NL38212</org_study_id>
    <nct_id>NCT02105506</nct_id>
  </id_info>
  <brief_title>Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses</brief_title>
  <acronym>SAFE-T</acronym>
  <official_title>Safety and Feasibility of TachoSil®: Application on Esophageal Anastomoses</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R. van Hillegersberg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>UMC Utrecht</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Rationale: The construction of esophageal anastomoses is associated with considerable risk at&#xD;
      postoperative anastomotic leakage. Application of TachoSil®, a tissue sealant with human&#xD;
      fibrinogen and thrombin, can improve strength of the esophageal anastomosis and potentially&#xD;
      prevent anastomotic leakage.&#xD;
&#xD;
      Objective: Evaluation of feasibility and safety of TachoSil® application on esophageal&#xD;
      anastomoses.&#xD;
&#xD;
      Study design: Non-randomized, non-blinded, single-center intervention study. Study&#xD;
      population: Patients, 18-80 years old, undergoing an elective total gastrectomy with an&#xD;
      esophago-jejunostomy or esophagectomy with a planned esophagogastric anastomosis will be&#xD;
      enrolled. A total number of 15 patients will be included in the study.&#xD;
&#xD;
      Intervention: Gastric or esophageal resection will be executed according to the common&#xD;
      procedures used in the UMC Utrecht. After construction of the esophageal anastomosis, all&#xD;
      enrolled participants will receive a TachoSil® patch, which will be applied on the esophageal&#xD;
      anastomosis intra-operatively. Hence, TachoSil® is used as an add-on therapy. TachoSil® will&#xD;
      be degraded enzymatically in a period of approximately 24 weeks after application.&#xD;
&#xD;
      Main study parameters/endpoints: The primary endpoint is feasibility, which is assessed by&#xD;
      evaluation of adherence of the patch. A time-action analysis of the application of the&#xD;
      Tachosil patch will be performed.&#xD;
&#xD;
      Nature and extent of the burden associated with participation: The burden for the patient is&#xD;
      minimal. The total surgical procedure will be prolonged with 10-15 minutes. Postoperative&#xD;
      care and outpatient visits do not differ from regular protocol. TachoSil® is approved and&#xD;
      registered for supportive treatment in surgery for improvement of haemostasis and to promote&#xD;
      tissue sealing by the European Commission.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">December 2014</completion_date>
  <primary_completion_date type="Actual">December 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>Surgical procedure</time_frame>
    <description>The adherence of the Tachosil patch</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>all cause mortality</measure>
    <time_frame>within the first 30 days (plus or minus 3 days) after surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Esophageal Disease</condition>
  <condition>Gastric Disease</condition>
  <arm_group>
    <arm_group_label>Tachosil patch</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tachosil patch (9.5 x 4.8 cm), containing human fibrinogen (5.5 mg/cm2) and human thrombin (2.0 IU/cm2), applied during surgery. Up to 7 patches per participant may be applied.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tachosil patch</intervention_name>
    <arm_group_label>Tachosil patch</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients undergoing an elective total gastrectomy with an esophago-jejunostomy or&#xD;
             esophagectomy with a planned esophagogastric anastomosis&#xD;
&#xD;
          -  Male and female gender&#xD;
&#xD;
          -  Ages 18-80&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  For females of childbearing potential:&#xD;
&#xD;
               -  Patient uses a reliable contraceptive method: contraceptive pill, intrauterine&#xD;
                  device, subdermal implantation, or transdermal patch&#xD;
&#xD;
               -  Patient has a negative serum or urine pregnancy test.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Emergency resections of esophagus of stomach&#xD;
&#xD;
          -  Unsigned informed consent&#xD;
&#xD;
          -  History of hypersensitivity reactions to human fibrinogen, human thrombin, or&#xD;
             collagen.&#xD;
&#xD;
          -  Patients having difficulty understanding Dutch and English&#xD;
&#xD;
          -  Mentally incapable patients&#xD;
&#xD;
          -  Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Medical Center Utrecht</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2015</verification_date>
  <study_first_submitted>April 2, 2014</study_first_submitted>
  <study_first_submitted_qc>April 4, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2014</study_first_posted>
  <last_update_submitted>April 23, 2015</last_update_submitted>
  <last_update_submitted_qc>April 23, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 24, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>UMC Utrecht</investigator_affiliation>
    <investigator_full_name>R. van Hillegersberg</investigator_full_name>
    <investigator_title>Prof. R. van Hillegersberg, surgeon</investigator_title>
  </responsible_party>
  <keyword>Esophagus</keyword>
  <keyword>Stomach</keyword>
  <keyword>Resection</keyword>
  <keyword>Esophageal disease requiring surgery</keyword>
  <keyword>Gastric disease requiring surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Diseases</mesh_term>
    <mesh_term>Stomach Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

